Contineum director awarded 19,000 CTNM stock options
Contineum Therapeutics director Evert B. Schimmelpennink received a routine equity grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics director Evert B. Schimmelpennink received a routine equity grant. He was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the 2024 Equity Incentive Plan. These options vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting and expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Schimmelpennink Evert B.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Key Figures
Option grant size: 19,000 shares
Exercise price: $14.19 per share
Expiration date: June 25, 2036
+3 more
6 metrics
Option grant size
19,000 shares
Stock Option (right to buy) for Class A Common Stock
Exercise price
$14.19 per share
Conversion or exercise price of stock options
Expiration date
June 25, 2036
Option expiration for director grant
Shares underlying options
19,000 shares
Underlying Class A Common Stock covered by the options
Holdings after grant (options)
19,000 derivative shares
Total stock options following the transaction
Vesting date trigger
June 26, 2027 or next annual meeting
Options vest on earlier of these dates, subject to service
Key Terms
2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, Class A Common Stock
4 terms
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"),"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended,"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Contineum Therapeutics (CTNM) disclose in this Form 4 filing?
Contineum Therapeutics reported a grant of stock options to director Evert B. Schimmelpennink. He received options for 19,000 Class A Common shares as part of the company’s 2024 Equity Incentive Plan and non-employee director compensation program.
What is the exercise price and term of the new Contineum Therapeutics options?
The granted stock options have an exercise price of $14.19 per share and expire on June 25, 2036. This means the director can purchase 19,000 shares at $14.19 any time before the expiration date, once the options are vested.
When do Evert B. Schimmelpennink’s CTNM stock options vest?
The options vest in full on the earlier of June 26, 2027 or Contineum Therapeutics’ next regular annual stockholder meeting. Vesting is contingent on the director’s continuous service on the company’s Board of Directors through the applicable vesting date.
Is this CTNM Form 4 transaction a stock purchase or sale on the market?
No, this Form 4 reflects a grant of stock options as compensation, not an open-market trade. The director did not buy or sell CTNM shares; instead, he received the right to purchase 19,000 shares later at a fixed exercise price.
Under which plan were the Contineum Therapeutics options granted to the director?
The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan, pursuant to its Non-Employee Director Compensation Program. That program automatically grants 19,000-share stock options to each continuing non-employee director after each regular annual stockholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates